The drug, known as BDTX-1535, is being investigated in patients with glioblastoma that harbors EGFR alterations and non-small cell lung cancer that harbors EGFR mutations of intrinsic or acquired resistance and disease that has failed standard treatment.
Once a recommended dose of the drug is determined, the study investigators will review the efficacy and safety associated with this treatment across a variety of patients with bladder and liver cancer, as well other solid tumors.
The plan to launch the phase 1 trial to evaluate the safety and efficacy of combining the CAR-T cell therapy and oncolytic virus in patients with recurrent glioblastoma, a type of brain cancer, is supported by interim data from two ongoing trials.
The plan, according to the San Diego-based pharmaceutical company, is to launch a phase 3 trial to analyze the safety and efficacy of a novel drug in mantle cell lymphoma in the second half of 2022.
The primary focus of the trial is to evaluate the incidence of treatment-emergent and serious side effects in patients receiving either the novel drug alone or in combination with Keytruda.
Earlier in the year, clinical trials assessing magrolimab for myelodysplastic syndrome and acute myeloid leukemia were put on a partial clinical hold, but now the FDA said that they can start enrolling patients again.
The Food and Drug Administration granted a fast-track designation to Bria-IMT for the treatment of patients with metastatic breast cancer.
Investigators plan to enroll approximately 90 patients with squamous cell carcinoma of the head and neck, as well as metastatic bladder and non-small cell lung cancer.
A phase 2 trial will investigate LTX-315 in patients with basal cell carcinoma, the most common form of skin cancer.
The first patient was dosed in an early-phase trial evaluating the investigational cell therapy DeTIL-0255 for the treatment of advanced ovarian, cervical and endometrial cancer.
Researchers have treated the first patient in the PRECISION 1 trial with Fyarro to assess the drug’s efficacy across several endpoints including survival among more than 100 patients with solid tumors that exhibit certain genetic alterations.
An upcoming phase 2 study will explore if the transdermal (through the skin) delivery of a drug commonly used to treat nausea and vomiting will result in no nausea, no vomiting and no use of rescue medicines in patients with cancer receiving chemotherapy.
The plan is to assess the safety and efficacy of the genetically engineered cell therapy alongside high-dose chemotherapy and blood stem cell transplantation in approximately 150 patients with lymphoma.
A patient with an advanced solid tumor was given their first dose of a novel antibody, kicking off a phase 1/1b study comparing this drug with or without Keytruda in patients with several types of solid tumors.
It is expected that up to 18 patients with leptomeningeal metastases — a serious form of cancer that has spread from its original location to an area surrounding the brain and spinal cord — will receive treatment with the investigational drug.
Approximately 60 patients with metastatic/unresectable solid tumors, including bladder cancer, are expected to be enrolled onto a clinical trial assessing the safety and efficacy of Zepzelca.
The study authors plan to enroll 24 patients with glioblastoma, an aggressive brain tumor, to assess the efficacy an investigational drug plus Libtayo prior to surgery to remove the tumor.
The trial will be testing TARA-002 in patients with non-muscle invasive bladder cancer with high-grade carcinoma in situ and high-grade papillary tumors.
MRX0518 plus Keytruda led to a clinical benefit in four out of 16 evaluable patients with renal cell carcinoma. The drug duo will continue to be studied for multiple types of solid tumors.
Approximately 100,000 patients with stage 1 to stage 3 solid tumors will be enrolled onto the trial across 25 sites, according to the manufacturer of the test aimed at detecting cancer recurrence.
The early-stage trial, according to the investigational drug’s manufacturer, Adagene, is expected to take place across multiple sites in the United States and Asia Pacific.
Four sites across the United States are enrolling patients with locally advanced or metastatic pancreatic cancer to see if a novel drug combined with standard-of-care chemotherapy bests chemotherapy alone in survival outcomes and responses to treatment.
The rare cancer, known as adenoid cystic carcinoma, is diagnosed in fewer than 1,500 people in the United States each year and is often found in the salivary glands, a part of the body associated with helping a person swallow and digest food.
The study authors plan to enroll 32 patients with advanced pancreatic cancer into the trial to assess the efficacy and safety of an experimental treatment combination.
The goal of the phase 2 trial is to study the safety and efficacy of ASP-1929, a photoimmunotherapy with fluorescence imaging, in patients with head and neck or skin cancer.
A trial to examine BMF-219 in patients with relapsed or refractory acute leukemias has begun recruiting patients across multiple U.S. states.
A phase 3 trial evaluating the safety and efficacy of the BTK inhibitor LOXO-305 in patients with previously treated mantle cell lymphoma is now open to patients across more than a dozen states.
A phase 2b clinical trial evaluating the efficacy and safety of an immunotherapy drug for patients with brain cancer has opened at Roswell Park Comprehensive Cancer Center in Buffalo, New York, with additional plans to be carried out at more than a dozen sites.
After preliminary results showed promise for the combination, researchers are expanding their clinical trial for PDS0101 plus Keytruda in HPV-related head and neck cancer.
A phase 1/2a clinical trial examining the effects of a treatment called LAVA-1207 for patients with metastatic prostate cancer has now begun.
